At Cardiomatics, we are committed to advancing cardiac research with AI-driven ECG analysis. We are proud to share our latest study, conducted with University Hospital Basel, and published in Diabetes Care. This marks our fourth collaboration, and we are eager to do more!
The study explores how metformin can protect against the harmful effects of glucocorticoids (GCs). These commonly used anti-inflammatory drugs often cause insulin resistance, high cholesterol, and muscle loss. A key focus of the research was heart rate variability (HRV)—analyzed using our AI-powered ECG technology.
Why This Study Matters
Glucocorticoids help treat asthma, autoimmune diseases, and chronic inflammation. However, long-term use can lead to serious health risks:
- Higher risk of diabetes due to insulin resistance
- Heart problems caused by changes in fat metabolism
- Muscle and bone loss, making the body weaker
Metformin, a well-known diabetes drug, may help counteract these effects. But how does it work? This study aimed to find out.
The Role of AI-Driven ECG in the Study
To measure autonomic nervous system function, researchers used Cardiomatics’ AI-powered ECG analysis. HRV is a key indicator of heart and metabolic health. It shows how well the body adapts to stress and regulates heart function.
Although HRV did not change significantly, the study provides valuable data for future research. Understanding HRV in this context may help improve treatments for metabolic disorders.
This is our fourth research project with University Hospital Basel, and we are excited about what’s next. Our work spans cardiac electrophysiology, metabolic research, and AI-driven ECG analysis. Together, we are shaping the future of cardiology and digital health.
We are eager to collaborate with hospitals, universities, and research teams exploring AI-driven ECG analysis. Whether you study HRV, arrhythmias, long-term ECG monitoring, or metabolic health, our platform can help.
Read the full study here.